Meihua Sui received her M.D. and Ph.D. from Zhejiang University School of Medicine in 1999 and 2011, respectively. She once worked as a Postdoctoral Fellow and then as a Research Assistant Professor in the Medical University of South Carolina in USA between 2002 and 2009. Then she joined the College of Chemical and Biological Engineering at Zhejiang University as a Professor & Associate Director for Center for Bionanoengineering in the spring of 2009. She moved to Zhejiang Provincial People’s Hospital in 2015, as Professor, Principle Investigator and Associate Director of Clinical Research Institute & Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province. In April 2020, she joined the Zhejiang University School of Medicine as Professor and Principle Investigator. Her research interests include R&D on anti-cancer modalities, mechanisms and reversal of drug resistance, and impact of steroid hormones on cancers. She has received many awards, such as Recipient of National Natural Science Foundation for Excellent Young Scientists and Recipient of Zhejiang Provincial Natural Science Foundation for Distinguished Young Scientists. She has been an academic reviewer for more than 30 peer-reviewed scientific journals, including Materials Today, Biomaterials, ACS Applied Materials & Interfaces, Molecular Therapy, etc. Meanwhile, she has been serving as an Ad Hoc Reviewer for many Foundations of China including National Natural Science Foundation. Dr. Sui has published more than 70 scientific papers on peer-reviewed journals, contributed to 3 books internationally published, and received 10 invention patents. In addition, through collaboration with Xcovery Inc. in the United States, she and her collaborators validated three novel compounds named as vorolanib/X-82/CM082, ensartinib/X-396 and X-379/CM118, respectively, all of which are potent kinase inhibitors. These compounds have been advanced to clinical trials in both US and China, with very promising clinical data achieved.